GlassScriptPhysician profile
George R Simon
NPI 1164438768
$92,144.36
in general payments reported to CMS, 2019-2025
19 companies · $19K in 2025
The $19K reported for 2025 was more than what 88% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $1,800 · 2021: $13K · 2022: $477 · 2023: $17K · 2024: $16K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Honoraria: $8,350 · Travel and Lodging: $3,311 · Food and Beverage: $1,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,521.10 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,823.30 |
| Honoraria | $8,350.00 |
| Travel and Lodging | $3,311.33 |
| Food and Beverage | $1,522.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $28,130.92 | 2019-2025 | Imfinzi, Tagrisso |
| Novocure INC. | $21,627.93 | 2019-2025 | Optune Lua (Novottf-200t), Optune Gio |
| Regeneron Healthcare Solutions, INC. | $17,285.27 | 2021-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $9,046.26 | 2019 | |
| Pfizer INC. | $6,093.81 | 2019 | |
| Jazz Pharmaceuticals INC. | $3,120.00 | 2023 | |
| Reflexion Medical, INC. | $1,800.00 | 2020 | |
| Daiichi Sankyo INC. | $1,715.94 | 2024 | Enhertu |
| Janssen Scientific Affairs, LLC | $1,121.78 | 2021-2023 | Rybrevant |
| Abbvie INC. | $980.94 | 2025 | |
| Coherus Oncology, INC. | $525.01 | 2022-2025 | Loqtorzi |
| Genentech USA, INC. | $287.51 | 2019-2023 | Tecentriq |
| Glaxosmithkline, LLC. | $114.95 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.38 | 2019-2023 | |
| Janssen Biotech, INC. | $70.77 | 2021-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $38.48 | 2023 | Gavreto, Avastin, Rozlytrek |
| Bayer Healthcare Pharmaceuticals INC. | $31.46 | 2025 | |
| Merck Sharp & Dohme LLC | $27.92 | 2023 | |
| Lilly USA, LLC | $23.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.